BC Week In Review | Aug 3, 2015
Company News

Intrexon, Oragenics deal

Intrexon granted Oragenics exclusive, worldwide rights to develop and commercialize biotherapeutics based on the ActoBiotics genetically modified Lactococcus lactis platform, including AG013 , to treat oral mucositis (OM) and other diseases of the oral cavity, throat...
BC Week In Review | Feb 16, 2015
Company News

ActoGeniX, Intrexon deal

Synthetic biology company Intrexon will acquire ActoGeniX for $60 million, comprising $30 million in cash and $30 million in stock. Intrexon will gain ActoGeniX’s TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms....
BC Extra | Feb 14, 2015
Company News

Intrexon acquires mucosal therapeutics play ActoGeniX

Synthetic biology company Intrexon Corp. (NYSE:XON) will acquire ActoGeniX N.V. (Zwijnaarde, Belgium) for $60 million. Intrexon will gain ActoGeniX's TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms, and a pipeline including two...
BioCentury | Jul 28, 2014
Finance

Gut reaction

Gut reaction Synlogic Inc. is using its $29.4 million series A round to develop engineered microbes that could enable more fine-tuned delivery of therapeutic proteins than other bacterial delivery platforms, as well as have a...
BC Innovations | May 10, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes CD3; insulin (INS; proinsulin); IL-10 Studies in mice suggest Lactococcus lactis engineered to secrete both IL-10 and proinsulin could help treat type 1...
BC Week In Review | Sep 26, 2011
Clinical News

AG013: Phase Ib data

A single-blind, U.S. Phase Ib trial in 19 patients receiving induction chemotherapy showed that AG013 led to a 35% reduction in the percentage of days with ulcerative OM vs. placebo. Additionally, about 30% of patients...
BC Week In Review | Aug 24, 2009
Clinical News

AG013: Phase Ib started

ActoGeniX began a single-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial to evaluate topical AG013 given 1, 3 or 6 times daily in 21 patients. ActoGeniX N.V. , Zwijnaarde, Belgium   Product: AG013   Business: Other  ...
BC Week In Review | May 18, 2009
Clinical News

AG013: Phase Ib start

Next month, ActoGeniX will begin a single-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial to evaluate AG013 given one, three or six times daily in 21 patients. ActoGeniX N.V. , Ghent, Belgium   Product: AG013   Business:...
Items per page:
1 - 8 of 8